drug

NTLA-2002

1 story · latest Sep 8, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Intellia Therapeutics

Timeline

FDA accepts Intellia's BLA for lonvo-z in hereditary angioedema, grants priority review

Sep 8Regulatory milestoneIntellia Therapeutics

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.